PureTech Health plc — Capital/Financing Update 2021

Feb 5, 2021

6-K 1 d108074d6k.htm 6-K 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For February 5, 2021

Commission File Number 001-39670

PURETECH HEALTH PLC

6 Tide Street, Suite 400

Boston, Massachusetts 02210

Attention: Chief Executive Officer

(617) 482-2333

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On February 5, 2021, PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) issued a press release announcing that its Founded Entity, Vor Biopharma, has publicly announced the pricing of its initial public offering. The press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

Exhibits

99.1 Press Release dated February 5, 2021, “PureTech Founded Entity Vor Biopharma Announces Pricing of Initial Public Offering”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

/s/ Daphne Zohar
Name:	Daphne Zohar
Title:	Chief Executive Officer